目的：研究BRMS1基因在前列腺癌中的表达及临床意义。方法收集我院2008年1月至2011年5月期间行前列腺癌根治术后的石蜡包埋标本80例，良性前列腺增生（BPH）组织石蜡包埋标本35例。应用免疫组化超敏型二步法，检测前列腺癌和BPH组织中BRMS1的表达情况，分析 BRMS1的表达与临床病理参数之间的关系。结果 BRMS1蛋白在前列腺癌和BPH组织中的阳性表达率分别为40.00%（32/80）和74.29%（26/35），差异具有统计学意义（P＜0.05）。BRMS1蛋白阳性表达率与前列腺癌的T、M分期和Gleason评分呈负相关，差异有统计学意义（P ＜0.05）；BRMS1蛋白阳性表达率与前列腺癌的年龄、淋巴结转移无相关性，差异没有统计学意义（P＞0.05）。结论 BRMS1蛋白在前列腺癌组织中低表达或不表达，可能与前列腺癌的临床分期和病理分级有关。%Objective To study the expressions of the BRMS1 gene in prostate cancer and its clinical significance. Methods Total of 80 samples of prostate cancer and 35 samples of benign prostate hyperplasias were collected from our hospital during January, 2008 to May, 2011. The expression of BRMS1 was detected by immunohistochemistry. Then the correlation between the expression level of BRMS1 and the clinical pathological parameters was analyzed. Results The positive expression rates of BRMS1 were 40.00%(32/80)and 74.29%(26/35) respectively in prostate cancer and benign prostate hyperplasia with a significantly statistical difference(P<0.05).The expression of BRMS1 was negatively correlated with the Gleason score, T stage and M stage of prostate cancer (P<0.05). But the expression of BRMS1 was not correlated with age and lymph nodes metastasis in the prostate cancer(P>0.05). Conclusion The abnormal expression of BRMS1 indicates that BRMS1 may be related to the clinical stage and different pathology grade of prostate cancer.
展开▼
